City of Hope and Translational Genomics Research Institute (TGen) announced plans to form an alliance earlier this week to develop a cell therapy manufacturing facility in Phoenix. California-based City of Hope is branching out from its California roots with multiple facilities in Duarte, California.
As an independent cancer research and treatment center, City of Hope currently has three manufacturing practices in California, which provides biological and chemical Good Manufacturing Practice (GMP) all in one place.
Addressing the need for this alliance, Robert Stone, president and CEO of City of Hope said in a press release:
“Patients want choices and access to the newest and most advanced care available.”
The alliance aims to deliver this kind of access by using precision medicine, which Steven Rosen chief scientific officer for City of Hope calls, “the future of cancer care.” The demand for clinical cell therapies is growing and most manufacturing facilities are reaching their maximum capacity due to demand overwhelming productivity.
TGen is based in Arizona with headquarters in Phoenix and as part of the deal, it will become a subsidiary City of Hope’s parent company.
“This significant investment further enhances Arizona’s reputation as a hub for bioscience and health care innovation,” remarked Gov. Doug Ducey in a statement.
For more information on the companies and their alliance check out the press release.
Or take a look at News Medical’s article.